Multiple sclerosis (MS) is a chronic inflammatory demyelinating and neurodegenerative disease that disproportionately affects young adults, leading to disability and high costs to society. Infiltration of T cells and monocytes into the central nervous system (CNS) is critical for disease initiation and progression. However, despite a great deal of effort the molecular mechanisms by which immune cells initiate and perpetuate CNS damage in MS have not yet been elucidated. In experimental autoimmune encephalomyelitis (EAE), an animal model of MS, granulocyte-macrophage colony-stimulating factor (GM-CSF) produced by pathogenic Th1 and Th17 cells is critical for the recruitment of monocytes into the CNS during the initial stage of disease. We and others have recently shown that, compared with healthy individuals, MS patients have greater numbers of CD4 + and CD8 + T cells that produce GM-CSF. Here, we describe the expression of GM-CSF and its receptor, GM-CSFR, in normal brain and MS lesions. Our data show that in acute and chronic MS lesions, microglia and astrocytes have upregulated expression of GM-CSFR; in addition, we show that GM-CSF-associated molecules are also upregulated in MS lesions. These findings further strengthen the argument that GM-CSF signaling contributes to MS pathogenesis.
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Introduction
Multiple sclerosis (MS) is an inflammatory demyelinating and neurodegenerative disease of the central nervous system (CNS). MS is characterized by infiltration of immune cells into the CNS, where they cause damage to myelin, oligodendrocytes, and axons, as well as neuronal dysfunction (Imitola et al., 2006) . Although the etiology of MS remains elusive, the risk of developing MS is associated with genetic and environmental factors, including allelic variants in over 100 genes (International Multiple Sclerosis Genetics et al., 2011) . Environmental factors that increase risk of MS include vitamin D deficiency, EpsteinBarr virus infection early in life, and smoking (Ascherio, 2013). Current views of MS pathogenesis implicate trafficking of T cells into the brain, attracting other immune cells, primarily monocytes, and causing tissue damage. The migration of Leukocytes, including activated lymphocytes, monocytes and macrophages, into the brain is necessary to initiate pathology has been verified in humans by blocking antibody against the molecule VLA-4 (Natalizumab), which is critical for leukocytes migration. Natalizumab significantly decreases infiltration of immune cells into the CNS, leading to reduced disease activity, as shown by the decline in the number of gadolinium-enhancing lesions and improvement in disease activity (Nicholas et al., 2014) . Conversely, if this medication is stopped, allowing migration of T cells into the CNS, disease activity invariably returns, with, in some instances, risk of severe exacerbation and progression. This indicates that migration of T cells into the CNS and their interaction with resident cells is critical to the pathological process in MS (Kivisakk et al., 2009) . The mechanisms underlying the interaction of immune cells with resident CNS cells that leads to persistent immune activation are not known. It has been suggested that upon entry into the brain, T cells interact with microglia and astrocytes, and recruit monocytes and macrophages that play a critical role in initiating and maintaining an inflammatory environment that causes CNS damage (Frohman et al., 2006) .
The mechanisms of T cell activation and generation of pathological T cells in MS have been elucidated in MS models such as experimental autoimmune encephalomyelitis (EAE). From this work, we have learned
